Columbia, SC, July 10 – Following the announcement of the company’s public listing, Collexis (OTCBB: CLXS) has signed an Enterprise License Agreement and ongoing engagement with the National Institutes of Health (NIH), replacing the Company’s prior license with NIH. The National Institutes of Health is the largest funder of health sciences research in the world. Over $20B a year in federal grant funding will now be analyzed by the Collexis platform. The agreement also enables all the NIH Institutes to utilize the company’s software for categorization, search, expertise identification, discovery and analysis of text-based content. Content examples include publications, grants, patents and other scientific works and information.
“We are very excited about our relationship with the NIH and are confident Collexis will be a valuable asset to its 27 institutions. The Collexis analysis of grant content fits with the NIH’s Roadmap toward a digital future in research. Our software will help increase efficiency, consistency and transparency as it pertains to the Institutes’ needs,” said Bill Kirkland, CEO, Collexis Holdings, Inc.
This arrangement represents an important milestone for Collexis and adds another elite, first-mover institution to the ranks of those who have adopted Collexis’ research software, including Johns Hopkins University, Harvard University, Morehouse School of Medicine, University of California, San Francisco, University of South Carolina, Bristol-Myers Squibb, Merck & Co. Inc., Lockheed Martin, the World Health Organization, Wellcome Trust, and others. “With the addition of NIH and Wellcome Trust, Collexis has now become the grants categorization, management and reporting standard for the largest public and largest private health science research funders in the world,” stated Steve Leicht, Collexis VP of Sales. “The NIH has their pick of the best technology. We are gratified that NIH has used its expertise, time and talent to do the necessary examination and comparison and has selected Collexis as its provider of text analysis software. Clearly, Collexis is at the leading edge of the marketplace,” Leicht added.
The Collexis application suite fingerprints private and public health sciences databases including PubMed, Grants.gov, Clinical Trials data, Web Data and other sources/publications, as well as internal corporate and enterprise content for analysis.
Collexis Holdings, Inc.
Collexis Holdings, Inc., a global knowledge discovery company since 1999, is headquartered in Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The Netherlands. Collexis’ patented technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content to create applications. The results are often described as “finding needles in many haystacks.” Through this novel approach, Collexis can build unique applications to search, index, and aggregate information as well as prioritize, trend and predict data based on sources in multiple fields, without the limitations of language or dialect. The company’s mission is to develop software supporting knowledge retrieval and discovery across multiple industries. For more information visit www.collexis.com.
This press release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to future outcomes. Factors that could affect future performance include business and economic trends, the ability to continue funding operating losses, fluctuations in operating results, continued success in developing our research software and other risk factors as disclosed in our public filings with the Securities and Exchange Commission.
National Institutes of Health (NIH) is not considered a supporter or partner of Collexis. Reference to NIH in the above shall not be construed as a Government endorsement nor does it obligate NIH to a position on or about the Collexis Software.